Actively Recruiting
Evaluating Different Doses of CLR 125 in Patients With Relapsed or Refractory Triple Negative Breast Cancer
Led by Cellectar Biosciences, Inc. · Updated on 2026-10-08
60
Participants Needed
4
Research Sites
73 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and proper dosing of the drug CLR 125 in patients with advanced triple negative breast cancer, a type of breast cancer that lacks certain hormone receptors. This Phase 1 trial aims to find the best dose and treatment schedule for future studies while monitoring side effects and antitumor activity, including treatment response and survival outcomes. The study is sponsored by Cellectar Biosciences, Inc. and plans to enroll up to 60 patients. Participants receive CLR 125 through an intravenous infusion given four times per cycle, with each cycle lasting eight weeks. There are several dosing groups with different dose levels and schedules, and participants may receive up to four cycles depending on the group. Some patients will also receive a single dose of CLR 131 to measure radiation delivery, undergoing scans and blood draws during this dosimetry phase. During the trial, participants visit the clinic every three weeks for checkups and tests. They will report any side effects or new medications throughout the study, which includes follow-up for up to one year after treatment ends. Researchers assess safety by tracking side effects and measure efficacy through tumor response rates, progression-free survival, overall survival, and duration of clinical benefit.
CONDITIONS
Brief Title
Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
Research Team
K
Kate Oliver
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here